RECOVER - Phase 2 COVID-19 subgroup
The population is composed of healthcare workers who participated in the first phase of the RECOVER study and will receive a COVID-19 vaccine. The first vaccine dose is administered around 8.4 ± 2.3 months (range: 0.8-13.1 months) after a PCR-confirmed SARS-CoV-2 infection. The second dose is offered 16 ± 6 weeks after the first dose.
The population is composed of healthcare workers who participated in the first phase of the RECOVER study and will receive a COVID-19 vaccine. The first vaccine dose is administered around 8.4 ± 2.3 months (range: 0.8-13.1 months) after a PCR-confirmed SARS-CoV-2 infection. The second dose is offered 16 ± 6 weeks after the first dose.
-
Newborns
-
-
Twins
-
-
Countries
-
-
Territory
-
-
Ethnic Origin
-
-
Health Status
-
Participants must have had a PCR-confirmed COVID-19 infection prior to enrollment.
Participants included in this study are selected based on their reported symptomatology at the time of infection and their serostatus at enrollment in the study.
-
Other Criteria
-
Participants must be healthcare workers from phase 1 of the RECOVER study. They are selected if their blood samples are available before and after vaccination.
-
Supplementary Information about selection criteria
-
Symptomatic participants are matched with asymptomatic participants based on their sex, age, ethnicity, and times of infection and vaccination.
-
Sources of recruitment
-
-
Participants from existing studies
-
Supplementary Information
-
Participants are recruited from the Phase 1 COVID-19 group of the RECOVER study.
-
Participants from Existing Studies
-
- REinfection in COVID-19 Estimation of Risk (RECOVER)
-
Number of Participants
-
25
-
Number of Participants with Biological Samples
-
25
-
Supplementary Information about selection criteria
-